IMRX
Immuneering Corporation
NASDAQ · Healthcare · Biotechnology · US
$4.82
−4.37%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +2.8%
- EBIT
- +0.9%
- EPS
- +45.0%
- Free cash flow
- -10.6%
- Operating cash flow
- -10.2%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- -29.7%
Three-year CAGR
- Revenue
- —
- EBITDA
- +13.1%
- EBIT
- +7.3%
- Net income
- +8.2%
- EPS
- +37.7%
- Free cash flow
- +17.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026